Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers

• DOI: 10.1111/cts.13566
• Publication Date: 2023-06-07T14:54:04Z
• Authors: Dasohm Kim; Minkyu Choi; Byung Hak Jin; Taegon Hong; Choon Ok Kim; Byung Won Yoo; Min Soo Park
• Keywords: Empagliflozin; Dapagliflozin; Pharmacodynamics; Crossover study; Dipeptidyl peptidase-4 inhibitor

Evogliptin (EV) is a novel dipeptidyl peptidase-4 inhibitor (DPP4i) for glycemic control in patients with type 2 diabetes mellitus (T2DM). This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV sodium glucose cotransporter-2 inhibitors (SGLT2i) healthy volunteers since combination therapy of DPP4i SGLT2i has been considered as an effective option T2DM treatment. A randomized, open-label, multiple-dose, two-arm, three-period, three treatments, two-sequence crossover was conducted Korean volunteers. In arm 1, subjects were administered 5 mg once daily 7 days, 25 empagliflozin (EP) days (EV + EP). 2, 10 dapagliflozin (DP) DP). Serial blood samples collected PK analysis, oral tolerance tests PD analysis. each arm, total 18 completed study. All adverse events (AEs) mild no serious AEs. The geometric mean ratio confidence interval main parameters (maximum concentration drug plasma at steady state area under concentration-time curve within dosing state) either EP or DP alone not significantly altered by co-administration. Administration did result significant changes, determined glucose-lowering effect. had effects on profiles drug. treatments well-tolerated.